Dravet syndrome

UCB sign

Pharma

Results for UCB's Fintepla pave way for 3rd epileptic indication

UCB plans to file for regulatory approval of Fintepla to treat a third epileptic condition “as soon as possible,” the company said.

Kevin Dunleavy Dec 8, 2025 11:19am

UCB's Fintepla shows potential to treat a 3rd epilepsy disorder

Jun 27, 2025 11:28am

Eisai

Eisai ends lorcaserin development in Dravet syndrome

Nov 18, 2024 10:18am

A graphic from UCBs Sound of Profound Moments Family Video Project

UCB bangs drum for epilepsy drug in ‘sound of profound’ videos

Jun 19, 2024 7:00am

Jazz Pharmaceuticals

NICE signs off on reimbursement for Jazz's cannabinoid med

Feb 1, 2023 11:52am

UCB sign

2 players vied before UCB emerged to buy Zogenix for $1.9B

Feb 1, 2022 5:24pm